Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KYMR - Kymera Therapeutics Inc


IEX Last Trade
48.42
0.170   0.351%

Share volume: 622,969
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$48.25
0.17
0.35%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 0%
Dept financing 7%
Liquidity 75%
Performance 2%
Company vs Stock growth
vs
Performance
5 Days
1.21%
1 Month
12.18%
3 Months
50.37%
6 Months
11.82%
1 Year
146.86%
2 Year
71.98%
Key data
Stock price
$48.42
P/E Ratio 
-18.92
DAY RANGE
N/A - N/A
EPS 
-$2.42
52 WEEK RANGE
$9.60 - $50.19
52 WEEK CHANGE
$1.44
MARKET CAP 
2.986 B
YIELD 
N/A
SHARES OUTSTANDING 
61.753 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$420,260
AVERAGE 30 VOLUME 
$437,759
Company detail
CEO: Nello Mainolfi
Region: US
Website: kymeratx.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.

Recent news